Table 1 AChR-ab titer, quantitative MG score, MGFA postintervention status, and concomitant drugs were assessed before and after the beginning with MMF treatment in 11 patients with AChR-ab positive MG.
nr./sex age | MGFA score | medication before MM treatment (mg) | reason for drug exchange | MMF duration (months) | Dose | serum level (Qg/ml) | concomitant treatment (mg) | MGFA postintervention status during MMF | change in status unchanged | QMGS | AChR-ab (nmol/l) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
before | after 1 | before | after 1 | ||||||||||
1. m/67 | I | PR 20 AZA 150 CH 360 | gGT increase (15-fold) | 46 | 2.0 g | 2.26 | none | complete pharmacologic remission | 0/24 | 0/24 | 21 | 17 | |
2. m/52 | I | PR 40 AZA 150 CH 240 | gGT increase (13-fold) | 16 | 2.0 g | 2.15 | none | minimal manifestations (mild ptosis) | unchanged | 3/24 | 3/24 | 3.6 | 10.4 |
3.m/59 | I | PR 20 CH 330 AZA 150 | gGT increase (5-fold) drug resistancy | 7 | 2.0 g | 2.43 | PR (7.5) | severe right ptosis CH (480) | unchanged | 3/24 | 3/24 | 5.0 | 2.3 |
36 | 1.5 g | (GI-problems) | CH (20) IVIG10g/month | minimal manifestation mild ptosis | improvement | 1/24 | 2.9 | ||||||
4.f/33 | I | PR 5 CH 270 AZA 150 | nausea, vomiting | 20 | 2.0 g | 2.97 | CH (180) | incomplete pharmacol. Remission after 20 mo generalization | exacerbation | 1/24 | 5/24 | 0.21 | 0.44 |
5.m/77 | IIa | PR 20 AZA 150(13-fold) CH 240 | gGT increase pancyopenia | 20 | 2.0 g 1.0 g | n.a. (flatulence) | none | pharmacologic remission | unchanged | 0/24 | 0/24 | 1.6 | 6.7 |
6.f/64 | IIa | PR 20 AZA 200 CH 240 | exacerbation | 36 | 2.0 g 2.5 g | 2.18 | CH (150) | complete pharmacologic remission | improvement | 7/24 | 3/24 | 31 | 39 |
7.f/20 | IIb | CH120 AZA 50 | edema (hand, feet) | 20 | 1.5 g | 0.72 | CH (240) | Complete pharmacol. remission | improvement | 6/24 | 4/24 | 43 | 22 |
8.f/43 | IIIa | PR 25 CH 240 AZA 150 | lymphopenia | 21 | 1.5 g | 1.90 | CH (240) | Complete pharmacol. remission | improvement | 4/24 | 0/24 | 44 | 34 |
9.m/64 | IIIa | PR CH AZA MTX | amylase/8 lipase increase nausea, vomiting | 2.0 g | n.a. | CH (345) | therapyresistancy | unchanged | 11/24 | 11/24 | 17 | 21 | |
10.f/33 | IIIb | CH 330 AZA 50 | recurrent 14 pancytopenia persistent sympt. | 1.0 g | 0.50 0.5 g | CH (270) | incomplete pharmacol. remission remission leucopenia | improvement | 5/24 | 1/24 | 7.5 | 11.5 | |
11.m/59 | V | PR 40 CH 540 AZA 150 | persistant sympt. | 26 | 2.0 g | 3.05 | PR (7.5) CH (480) | incomplete pharmacol. remission | improvement | 11/24 | 4/24 | 200 | 24 |